Steve Chesney
Stock Analyst at Redburn Atlantic
(2.58)
# 1,316
Out of 4,412 analysts
40
Total ratings
56.67%
Success rate
-0.53%
Average return
Main Sectors:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $77 → $54 | $44.85 | +20.40% | 7 | Feb 6, 2024 | |
| BIIB Biogen | Maintains: Neutral | $282 → $275 | $208.90 | +31.64% | 5 | Aug 8, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $167 → $170 | $146.14 | +16.33% | 6 | Aug 4, 2023 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $600 | $499.30 | +20.17% | 7 | Aug 2, 2023 | |
| ZTS Zoetis | Reiterates: Overweight | $225 | $158.42 | +42.03% | 2 | Jun 14, 2023 | |
| MRK Merck & Co. | Maintains: Overweight | $127 → $129 | $131.20 | -1.68% | 5 | May 1, 2023 | |
| ABBV AbbVie | Maintains: Neutral | $157 → $154 | $159.62 | -3.52% | 4 | Feb 10, 2023 | |
| PFE Pfizer | Maintains: Neutral | $50 → $46 | $25.40 | +81.10% | 2 | Feb 1, 2023 | |
| AMGN Amgen | Maintains: Underweight | $190 → $182 | $269.98 | -32.59% | 2 | Aug 9, 2022 |
Bristol-Myers Squibb Company
Feb 6, 2024
Downgrades: Neutral
Price Target: $77 → $54
Current: $44.85
Upside: +20.40%
Biogen
Aug 8, 2023
Maintains: Neutral
Price Target: $282 → $275
Current: $208.90
Upside: +31.64%
Johnson & Johnson
Aug 4, 2023
Maintains: Neutral
Price Target: $167 → $170
Current: $146.14
Upside: +16.33%
IDEXX Laboratories
Aug 2, 2023
Downgrades: Neutral
Price Target: $600
Current: $499.30
Upside: +20.17%
Zoetis
Jun 14, 2023
Reiterates: Overweight
Price Target: $225
Current: $158.42
Upside: +42.03%
Merck & Co.
May 1, 2023
Maintains: Overweight
Price Target: $127 → $129
Current: $131.20
Upside: -1.68%
AbbVie
Feb 10, 2023
Maintains: Neutral
Price Target: $157 → $154
Current: $159.62
Upside: -3.52%
Pfizer
Feb 1, 2023
Maintains: Neutral
Price Target: $50 → $46
Current: $25.40
Upside: +81.10%
Amgen
Aug 9, 2022
Maintains: Underweight
Price Target: $190 → $182
Current: $269.98
Upside: -32.59%